Maridebart Cafraglutide
MariTide · AMG 133
A conjugate pairing a GIP receptor antagonist antibody with GLP-1 receptor agonist peptides, studied in trials for weight management on a monthly schedule. Its design is the mirror image of the dual agonist approach, blocking the GIP receptor rather than activating it. Not approved.
Tracking and educational reference only, on values you enter or import yourself. Not medical advice or a dosing recommendation.
Regulatory status
Investigational
This substance is under study in humans, typically under a regulatory authorization such as an Investigational New Drug application. Investigational describes a stage of research and nothing more: it does not mean approval is coming, and it does not indicate that effectiveness has been established.
A regulatory status describes paperwork, not safety. An approved compound can still be wrong for a given person, and an unapproved one is neither thereby dangerous nor thereby fine.
Half-life
Long enough to support the once-monthly schedule used in trials. Half-life is an educational pharmacology figure, drawn from public sources, and is not a schedule or dosing instruction.
Storage & handling
Investigational; no approved label defines handling.
References
- NEJM 2025: once-monthly maridebart cafraglutide for the treatment of obesity, a phase 2 trial
Read the source
Common questions
Maridebart Cafraglutide, answered plainly.
01What is Maridebart Cafraglutide?+
A conjugate pairing a GIP receptor antagonist antibody with GLP-1 receptor agonist peptides, studied in trials for weight management on a monthly schedule. Its design is the mirror image of the dual agonist approach, blocking the GIP receptor rather than activating it. Not approved. It is also referred to as MariTide, AMG 133. It is listed here under GLP-1 / Metabolic as educational reference, which is not a recommendation to use it.
02Is Maridebart Cafraglutide FDA approved?+
Investigational. This substance is under study in humans, typically under a regulatory authorization such as an Investigational New Drug application. Investigational describes a stage of research and nothing more: it does not mean approval is coming, and it does not indicate that effectiveness has been established.
03What is the half-life of Maridebart Cafraglutide?+
Long enough to support the once-monthly schedule used in trials. A half-life is an educational pharmacology figure describing how long the body takes to clear half of a substance. It is not a schedule and does not imply one.
04How is Maridebart Cafraglutide stored and handled?+
Investigational; no approved label defines handling. Storage conditions come from a manufacturer's own label where one exists, and a compound with no approved label has no agency-reviewed handling instructions at all.
Related in GLP-1 / Metabolic
Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.